Ikena Oncology

Site - Secondary

  • Contact
  • LinkedIn
  • Twitter

Site - Top

  • About
    • Our Company
    • Leadership
    • Partners
    • Contact
  • Focus
    • Our Approach
    • Publications
  • Pipeline
    • Development Pipeline
    • IK-930 TEAD Inhibitor
    • IK-007 EP4 Antagonist
    • IK-175 AHR Antagonist
    • IK-412 Kynase Program
  • Careers
    • Culture
    • Job Opportunities
  • Investors & Media
    • Corporate Profile
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Financial Filings
    • Corporate Governance
    • Investor Resources
  • Site - Top

    • About
      • Our Company
      • Leadership
      • Partners
      • Contact
    • Focus
      • Our Approach
      • Publications
    • Pipeline
      • Development Pipeline
      • IK-930 TEAD Inhibitor
      • IK-007 EP4 Antagonist
      • IK-175 AHR Antagonist
      • IK-412 Kynase Program
    • Careers
      • Culture
      • Job Opportunities
    • Investors & Media
      • Corporate Profile
      • Press Releases
      • Events & Presentations
      • Stock Information
      • Financial Filings
      • Corporate Governance
      • Investor Resources
    • Contact
    • Privacy Policy
    • Terms of Use
    • LinkedIn
    • Twitter

SEC Filing Details

Document Details

Form
8-K
Filing Date
Mar 30, 2021
Document Date
Mar 25, 2021
Form Description
Report of unscheduled material events or corporate event
Filing Group
Current Reports
Company
Ikena Oncology
Issuer
IKENA ONCOLOGY, INC.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

Site - Side

  • Corporate Profile
  • Press Releases
  • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
  • Financial Filings
    • SEC Filings
  • Corporate Governance
    • Documents & Charters
    • Management Team
    • Board of Directors
  • Investor Resources
    • Investor FAQs
    • Investor Email Alerts
    • Contact IR

Investors & Media Contact

  • Argot Partners
  • (212) 600-1902
  • ikena@argotpartners.com

Tools

  • Print Page
  • Email Alerts
  • RSS Feeds
Footer Logo
Ikena Oncology
645 Summer Street
Suite 101
Boston, MA 02210
  • Privacy Policy
  • Terms of Use
Footer Logo
Ikena Oncology
645 Summer Street
Suite 101
Boston, MA 02210
  • About
  • Our Company
  • Leadership
  • Partners
  • Contact
  • Focus
  • Our Approach
  • Publications
  • Pipeline
  • Development Pipeline
  • IK-930 TEAD Inhibitor
  • RAS Signaling Program
  • IK-007 EP4 Antagonist
  • IK-175 AHR Antagonist
  • IK-412 Kynase Program
  • Careers
  • Culture
  • Job Opportunities
  • Investors & Media
  • Overview
  • Press Releases
  • Events & Presentations
  • Stock Information
  • Financials & Filings
  • Corporate Governance
  • Investor Resources
  • Privacy Policy
  • Terms of Use
  • LinkedIn
  • Twitter
© 2021 Ikena Oncology™